# Cathay Health

> Cathay Health is a VC fund in Paris backing Biotechnology, Big Data and Consulting. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Paris, France
- Total investments: 3
- Last investment: May 2023
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/showcase/cathay-health/
- Website: https://health.cathaycapital.com/

Cathay Health is a global fund investing at the convergence of healthcare, life sciences and technology.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Big Data | 1 | 33% |
| Consulting | 1 | 33% |
| Health Care | 1 | 33% |
| Therapeutics | 1 | 33% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Series C | 1 | 33% |
| Series D | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 1 | 33% |
| France | 1 | 33% |
| United Kingdom | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| TISSIUM | TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bindstrongly to tissues, and deliver on-demand wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC, and CapDecisif Management. | $53.8M | Series D | May 23, 2023 |  |
| Ascend Gene & Cell Therapies | Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form. | $65.9M | Series A | Mar 20, 2023 |  |
| DataStory | DataStory is a big data and AI intelligent business application provider. | $23.4M | Series C | Jun 16, 2021 |  |

3 of 3 investments shown.

## Co-investors
- [4BIO Capital](https://shizune.co/investors/profile/4bio-capital-partners) — VC Fund, 2 deals together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 2 deals together
- [DCVC Bio](https://shizune.co/investors/profile/dcvc-bio) — VC Fund, 2 deals together
- [Ajinomoto](https://shizune.co/investors/profile/ajinomoto) — VC Fund, 1 deal together
- [Crédit Mutuel Innovation](https://shizune.co/investors/profile/cm-cic-capital-innovation) — VC Fund, 1 deal together
- Deerfield Capital Management — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Cathay Health invest in?

Cathay Health invests primarily in Biotechnology, Big Data and Consulting startups, most often at Series A and Series C stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Cathay Health last invest?

The most recent investment recorded for Cathay Health closed in May 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co